Long-Covid /Child vaccine benefits: Synbiotic formula offers hope of microbiome-targeted therapies
A synbiotic formula (SIM01) developed by Hong Kong firm GenieBiome in collaboration with the Chinese University of Hong Kong has been shown to alleviate multiple symptoms of post-acute COVID-19 syndrome (PACS), while also benefiting children after their COVID-19 vaccination.
Source: foodnavigator-asia.com